Blue Jet Healthcare Shares Drop 10% as Q2 Profit Slips 10.8% to ₹52 Crore

Shares of Blue Jet Healthcare Ltd fell nearly 10% on Tuesday, November 4, following a decline in its quarterly earnings. The company’s net profit for the second quarter dropped 10.8% year-on-year to ₹52 crore, compared to ₹58.3 crore in the same quarter last year. The weak financial performance led to a notable reaction in the market as investors reassessed the near-term outlook.

Revenue and EBITDA Decline in the September Quarter

During the September 2025 quarter, revenue declined 20.6% to ₹165.4 crore from ₹208.2 crore reported in the corresponding period last year. The fall in revenue reflected slower demand across key product categories. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) also fell 21% to ₹55 crore from ₹69.4 crore a year ago. The operating margin contracted slightly to 33.1% from 33.3%, indicating cost pressures and weaker operating leverage.

About the Company and Core Operations

Blue Jet Healthcare, incorporated in 1968, focuses on manufacturing specialty pharmaceutical and healthcare ingredients. It produces contrast media intermediates, high-intensity sweeteners, and active pharmaceutical intermediates that cater to regulated markets. 

The company plays an important role in supplying key intermediates to leading global healthcare firms, with contrast media intermediates contributing over two-thirds of its total revenue in FY24.

Market Reaction and Stock Performance

The market reacted negatively to the quarterly numbers. As of November 04, 3:00 PM, Blue Jet Healthcare Share Price stood at ₹607, reflecting a 10% decline from the previous session. The stock has experienced significant volatility since listing in 2023, trading between ₹1,028 and ₹470 over the past year. The company’s market capitalisation currently stands at ₹10,535 crore, with a price-to-earnings (P/E) ratio of 29.5.

Financial Metrics and Outlook

Despite the recent decline in profit, the company maintains a solid financial position, supported by a return on capital employed (ROCE) of 39.8% and a return on equity (ROE) of 30.2%. However, the fall in revenue and margins in the latest quarter suggests that operational efficiency and demand stability will be key areas to watch going forward.

Read More:Snowman Logistics shares drop 5% after net loss in Q2, revenue rises 8.5%

Conclusion

The recent decline in Blue Jet Healthcare Share Price reflects investor caution after a soft quarterly performance. While short-term challenges persist, maintaining steady margins and improving operational efficiency could help the company sustain long-term business stability in the healthcare ingredient space.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.